Dermorphin
Dermorphin is a naturally derived heptapeptide widely utilized in preclinical neuropharmacology to investigate mu-opioid receptor binding kinetics and peptide degradation resistance. Characterized by its unique D-amino acid inclusion, this research compound provides laboratory investigators with a high-affinity tool for mapping central nervous system signaling pathways.
Quick answer
Dermorphin is a naturally derived heptapeptide widely utilized in preclinical neuropharmacology to investigate mu-opioid receptor binding kinetics and peptide degradation resistance. Characterized by its unique D-amino acid inclusion, this research compound provides laboratory investigators with a high-affinity tool for mapping central nervous system signaling pathways.
Key takeaways
- Dermorphin is a naturally derived heptapeptide originally isolated from the skin of South American *Phyllomedusa* frogs, renowned in preclinical pharmacology for its exceptional selectivity and potency as a mu-opioid receptor agonist.
- The primary amino acid sequence of dermorphin is H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2.
- Preclinical pharmacology demonstrates that dermorphin acts as a potent and selective agonist at the mu-opioid receptor (MOR), exhibiting sub-nanomolar affinity in competitive radioligand binding assays.
- Academic literature detailing the application of dermorphin spans several decades, primarily focusing on central nervous system pharmacology, analgesology models, and gastrointestinal transit assays in rodents.
Overview and Definition of Dermorphin
Dermorphin is a naturally derived heptapeptide originally isolated from the skin of South American *Phyllomedusa* frogs, renowned in preclinical pharmacology for its exceptional selectivity and potency as a mu-opioid receptor agonist. Containing a rare D-amino acid substitution (D-Alanine at position 2), dermorphin serves as a benchmark research compound for studying opioid receptor dynamics, peptide metabolic stability, and central antinociceptive signaling in laboratory models.
Unlike standard endogenous mammalian opioids such as enkephalins or endorphins, dermorphin demonstrates an unusually high resistance to enzymatic degradation by neutral endopeptidases and aminopeptidases. This enzymatic resilience is directly linked to its stereochemical configuration. As a specialized tool in biochemical research, high-grade dermorphin allows researchers to probe structural requirements for receptor activation without the rapid enzymatic clearance typical of L-amino acid peptides. Laboratories sourcing this compound through our catalog of research peptides utilize it strictly for *in vitro* binding assays, receptor dimerization studies, and controlled preclinical animal models.
Chemical Structure and D-Amino Acid Stereochemistry
The primary amino acid sequence of dermorphin is H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. The inclusion of D-alanine at position 2 is a crucial post-translational modification in amphibian skin peptides that serves as a focal point for structural biology research. In standard protein synthesis, ribosomal systems incorporate L-amino acids; however, non-ribosomal or post-translational epimerization mechanisms yield D-amino acid residues that profoundly alter peptide secondary structure.
The presence of D-Ala2 introduces a distinct turn in the peptide backbone, stabilizing a bioactive conformation that optimizes binding to the binding pocket of the mu-opioid receptor. Furthermore, this modification sterically hinders cleavage by circulating peptidases, thereby extending the biological half-life of the compound during *in vitro* incubations and tissue bath preparations. Researchers examining structural activity relationships (SAR) frequently compare dermorphin with conventional L-amino acid analogs to map the spatial requirements of G-protein coupled receptor (GPCR) activation, referencing data cataloged in our primary research library.
Mechanism of Action and Receptor Selectivity Profile
Preclinical pharmacology demonstrates that dermorphin acts as a potent and selective agonist at the mu-opioid receptor (MOR), exhibiting sub-nanomolar affinity in competitive radioligand binding assays. In comparative *in vitro* displacement studies using tissue homogenates and cell lines expressing cloned human receptors, dermorphin displays significantly higher selectivity for the mu-subtype relative to delta- (DOR) and kappa-opioid receptors (KOR).
Upon binding to the extracellular domain of the mu-opioid receptor, dermorphin triggers a conformational change that promotes intracellular coupling to heterotrimeric Gi/o proteins. This interaction inhibits adenylyl cyclase activity, reduces intracellular cyclic AMP (cAMP) accumulation, and modulates voltage-gated calcium channels while activating inwardly rectifying potassium channels. In cell culture models, these signaling cascades result in hyperpolarization of the neuronal membrane. Preclinical assays regularly measure these intracellular downstream effects to quantify agonist efficacy and evaluate GPCR desensitization or beta-arrestin recruitment profiles.
Preclinical Literature and Laboratory Findings
Academic literature detailing the application of dermorphin spans several decades, primarily focusing on central nervous system pharmacology, analgesology models, and gastrointestinal transit assays in rodents. In preclinical animal studies, central administration (such as intracerebroventricular injection in rodent models) of dermorphin has demonstrated potent antinociceptive actions at doses several orders of magnitude lower than morphine, attributable both to its high receptor affinity and resistance to enzymatic cleavage.
In addition to central nervous system research, *in vitro* organ bath experiments using isolated guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations have established dermorphin's ability to inhibit electrically stimulated smooth muscle contractions. These classical bioassays confirm its potent presynaptic inhibitory action on neurotransmitter release. Researchers also utilize dermorphin in cell-based assays to investigate receptor internalization, recycling kinetics, and tolerance development, making it an invaluable comparative reference alongside structural analogs such as dalargin and deltorphin.
Comparative Analysis: Dermorphin vs. Related Opioidergic Research Peptides
When evaluating peptidergic ligands for opioid receptor research, investigators often compare dermorphin against other synthetic and natural analogs. While dermorphin exhibits extreme selectivity for the mu-opioid receptor, related compounds like deltorphin display high affinity for the delta-opioid receptor, despite sharing structural similarities and originating from similar amphibian sources. Understanding these divergent selectivity profiles helps researchers dissect receptor-specific signaling pathways.
In contrast to dermorphin, the synthetic hexapeptide dalargin is a Leu-enkephalin analog modified with D-Ala to confer stability, primarily studied for peripheral tissue dynamics and cytoprotection rather than extreme central mu-potency. Furthermore, endogenous mammalian ligands like endomorphin-1 and endomorphin-2 lack D-amino acids, rendering them far more susceptible to rapid enzymatic hydrolysis in physiological buffers. For broader investigative contexts involving systemic peptide signaling, labs often compare these neuro-peptides against non-opioidergic tissue modulating peptides such as BPC-157 when assessing baseline cellular stability and peptide-receptor interactions.
Reconstitution, Handling, and Laboratory Storage Protocols
Dermorphin is supplied by PX1 Research as a lyophilized (freeze-dried) powder in sealed glass vials to ensure long-term chemical stability. To preserve peptide integrity and prevent premature hydrolysis, lyophilized vials should be stored upon receipt in a temperature-controlled freezer at -20°C or -80°C, protected from light and moisture.
For laboratory experimental preparation, reconstitution should be performed under aseptic conditions using sterile laboratory-grade solvents. Lyophilized dermorphin is readily soluble in sterile water, phosphate-buffered saline (PBS, pH 7.4), or dilute acetic acid solution. Investigators should avoid vigorous vortexing or mechanical agitation, which can induce peptide aggregation; gentle swirling or passive dissolution is recommended. Once reconstituted, stock solutions should be aliquoted into single-use polypropylene tubes to minimize freeze-thaw cycles and stored at -20°C or below for short-to-medium-term experimental use.
Supplier Quality Verification: RP-HPLC and Mass Spectrometry Testing
To guarantee reproducible experimental outcomes, research-grade peptides must adhere to rigorous analytical quality control parameters. PX1 Research enforces strict purity metrics for every lot of dermorphin distributed to academic, clinical, and institutional research facilities. Purity verification relies on two primary orthogonal analytical techniques: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS).
RP-HPLC analysis establishes the chromatographic purity of the sample, confirming that the total concentration of the target sequence exceeds defined threshold standards (typically ≥98% purity) without significant presence of truncated or deletion sequences. Concurrently, Mass Spectrometry confirms the exact molecular weight of the synthesized heptapeptide, verifying sequence identity and the correct incorporation of modified residues. Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) documenting these analytical spectrums.
Endotoxin Limits and Analytical Traceability Standards
In cell culture work, receptor binding assays, and *in vivo* preclinical rodent studies, contamination by bacterial endotoxins (lipopolysaccharides, LPS) can introduce significant experimental bias by activating innate immune receptors and confounding neurochemical measurements. PX1 Research performs quantitative Chromogenic Reagent Limulus Amebocyte Lysate (LAL) testing on every peptide production batch to verify that endotoxin levels remain below stringent laboratory research thresholds.
Furthermore, our manufacturing workflow incorporates comprehensive lot traceability. Every vial produced in our USA-based synthesis facilities is assigned a unique lot number linked to its raw material sourcing, synthesis conditions, purification logs, and ISO 17025 accredited third-party laboratory verification data. Academic and commercial entities managing wholesale research accounts gain full access to complete lot documentation packages required for institutional compliance and publication reproducibility.
Procurement and Sourcing Capabilities from PX1 Research
PX1 Research serves as a premier USA supplier of specialized research compounds, providing reliable sourcing for universities, biotechnology organizations, and independent research institutions. All peptide products are manufactured in state-of-the-art facilities compliant with Good Manufacturing Practice (GMP) standards, ensuring batch-to-batch consistency and minimal batch variance.
To support urgent research timelines and prevent experimental disruptions, PX1 Research maintains centralized inventory management with same-day shipping on orders placed Monday through Friday. Shipments originate directly from our distribution centers located in California and Arizona. Every order is packaged using secure, climate-conscious materials designed to preserve compound stability during transit, ensuring that researchers receive analytical-grade peptides ready for immediate laboratory preparation.
Frequently Asked Questions
What is the official research designation and primary target of dermorphin?
Dermorphin is a research-grade heptapeptide primarily studied in preclinical laboratory settings as a potent, highly selective agonist for the mu-opioid receptor (MOR).
Why is the presence of D-alanine structurally significant in dermorphin?
The incorporation of D-alanine at position 2 confers exceptional resistance against degradation by native proteolytic enzymes, while stabilizing a high-affinity bioactive conformation specific to mu-opioid receptors.
How should lyophilized dermorphin be stored upon delivery to the lab?
Lyophilized dermorphin powder should be stored in a dry, dark environment at -20°C or -80°C upon receipt to maintain molecular stability over extended periods.
What reconstituting solvents are recommended for dermorphin in laboratory assays?
Dermorphin can be reconstituted using sterile water for injection, sterile phosphate-buffered saline (PBS, pH 7.4), or a mild dilute acetic acid solution, depending on the specific requirements of the *in vitro* or preclinical assay.
What analytical methods are used by PX1 Research to confirm dermorphin purity?
PX1 Research utilizes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish sequence purity and Mass Spectrometry (MS) to verify exact molecular weight and identity.
Does PX1 Research provide lot-specific Certificate of Analysis (COA) documents?
Yes. Every lot of dermorphin is shipped with or accompanied by an accessible, batch-specific COA detailing HPLC purity percentages, MS identity verification, and endotoxin assay results.
How does dermorphin compare in selectivity to deltorphin?
While dermorphin is highly selective for the mu-opioid receptor, deltorphin—a structurally related amphibian peptide—is selective for the delta-opioid receptor, making them complementary tools for receptor-subtype comparative studies.
Is dermorphin suitable for human administration or clinical use?
No. Dermorphin is supplied strictly as a research chemical for laboratory *in vitro* and preclinical research applications. It is not for human or animal therapeutic, diagnostic, or clinical use.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.